Corporate ActionMay 27, 2026, 04:08 PM
Q32 Bio Announces $55M Private Placement Financing
AI Summary
Q32 Bio Inc. announced it has entered into a securities purchase agreement for a private placement of common stock and pre-funded warrants, expecting to raise approximately $55 million in gross proceeds. The offering includes 6,725,000 shares of common stock at $8.00 per share and pre-funded warrants to purchase 150,000 shares at $7.9999 per warrant. The net proceeds, combined with existing cash, will be used to advance clinical trials for bempikibart and for working capital and general corporate purposes. The private placement, led by BVF Partners L.P., is expected to close on May 28, 2026.
Key Highlights
- Q32 Bio secured approximately $55 million in gross proceeds from a private placement financing.
- The company sold 6,725,000 shares of common stock at $8.00 per share.
- Pre-funded warrants to purchase 150,000 shares were sold at $7.9999 per warrant.
- Net proceeds will fund clinical trials for bempikibart and for general corporate purposes.
- BVF Partners L.P. led the private placement, with participation from RA Capital Management, OrbiMed, and Atlas Venture.
- Morgan Stanley & Co. LLC acted as lead placement agent, with Oppenheimer & Co. Inc. as placement agent.
- The closing of the offering is expected on May 28, 2026.
Price Impact
More from QTTB